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A  is  often  the  case with  peptide growth  factors  and 
cytokines, the original activity discovered and identified 
as TGF-3 merely represented the tip of the iceberg. Not only 
does it regulate growth, as evident by its name, but TGF-B 
mediates far-ranging biologic processes including inflamma- 
tion and host defense, in addition to development, tissue re- 
pair, and tumorigenesis. Released locally from platelet stores 
early in an inflammatory response, TGF-3 is then generated 
by inflammatory cells themselves as part of the cytokine net- 
work. Initially, in its defensive role, TGF-~ mediates the egress 
of undifferentiated leukocytes and, subsequently, it facilitates 
resolution of inflammation and promotes tissue repair (1, 2). 
But  this  carefully  choreographed series  of events,  which 
represents  the "good" side of TGF-3, is dependent upon a 
critical balance of the growth factor. It is becoming increas- 
ingly evident that too much of a good thing can be bad; excess 
TGF-B within a lesion has been associated with unresolved 
inflammation and fibrotic events (1-3). Now, it appears, based 
on the study by Lowrance et al. (4) in the MRL/Ipr autoim- 
mune murine model, that TGF-3 has an even uglier side, 
in that its accumulation in the circulation may predispose 
the host to serious  and recurrent infections.  Moreover,  in 
humans, genetic and acquired diseases such as systemic lupus 
erythematosis (SLE) may mirror the MRL/lpr mouse. 
Under the best of circumstances,  TGF-3 provides a link 
between each of the processes by which cells and/or tissues 
respond to infection or injury and initiate repair. By increasing 
adhesion molecules, generating a potent chemotactic gradient, 
and inducing itself and an array of other factors as part of 
the cytokine network (5-7), TGF-~ orchestrates  leukocyte 
recruitment and activation. TGF-13 then downregulates these 
processes by inhibiting the functions of inflammatory cells 
once they are activated (2, 8) and facilitates healing by pro- 
moting fibroblast  recruitment and matrix synthesis (3). As 
recently reviewed (2), this apparent contradictory influence 
of TGF-3 on cells of the immune system, both stimulatory 
and inhibitory, is accounted for, in part by the differential 
effects of TGF-3 on resting and activated cells. As a general, 
but by no means exclusive rule, resting, immature ceils are 
stimulated by TGF-3, whereas activated  representatives  of 
the same cell populations may be inhibited by TGF-3. Thus, 
TGF-3  serves as a conversion factor,  converting an active 
inflammatory site into one dominated by resolution and re- 
pair. Upsetting the delicate balance of TGF-3 that dictates 
these events may have pathologic consequences. 
Indeed, persistent stimulation of immune/inflammatory 
events by internal or external challenges can overload the bal- 
ance with chronic secretion of TGF-B. Not only might this 
local excess lead to unresolved inflammation (9), but also, 
TGF-~/may reach the circulation. When elevated systemic 
levels of TGF-13 occur,  either endogenously during disease 
states (4,  10), or after exogenous administration (11-14), a 
plethora of additional cellular targets and consequently, di- 
verse signaling pathways with different outcomes, may be- 
come operative.  Although the source(s) of the endogenous 
levels of blood  TGF-/3  is  uncertain  in  the  autoimmune 
MRL/lpr mice, the spleen may contribute to the circulating 
pool in this and perhaps other models characterized by im- 
mune malfunction (4, 15). Why TGF-/~ accumulates is un- 
known, but TGF-/~ autoinduces its own synthesis (7). In ad- 
dition, dysregulation of its activity because of persistence of 
the enzymatic machinery essential for its activation or in- 
su~cient levels of inhibitors may be contributory. 
Nonetheless,  whereas  the  tightly controlled,  localized 
production of TGF-B occurs as a necessary component of an 
active inflammatory process, the aftermath of excess TGF-B, 
now found in the circulation, is to inhibit the same immune 
and inflammatory pathways. It is not inconceivable that this 
built-in negative feedback loop, occurring in TGF-B excess, 
evolved for the protection of the host during bouts of ram- 
pant inflammation. The dichotomy between local and sys- 
temically disseminated TGF-B was first documented in an 
experimental arthritis model in which local secretion or ad- 
ministration of TGF-13 was found to drive the inflammatory 
response, whereas systemic inoculation inhibited the same re- 
sponse (9,  13,  16) (Fig.  1). 
By what mechanism(s) does circulating TGF-3 promote 
immune suppression and can these pathways be used to clin- 
ical advantage? Recent evidence suggests that systemic TGF-13 
targets endothelial ceUs, where it inhibits E-selectin expres- 
sion to block adhesion and targeting of leukocytes to the site 
of inflammation (17) (Fig. 2). Moreover, since leukocytes are 
normally sensitive to a concentration gradient of chemotactic 
signals emanating from the site of inflammation (5, 9), the 
presence of elevated TGF-3 in the blood would destroy such 
an outward gradient (Fig. 2). Evidently, the effects of secreted 
or exogenous TGF-3 extend far beyond the control of cell 
growth and differentiation to include a myriad of other regula- 
tory activities converging on phagocytic cells and activated 
lymphoid cells of all lineages  (reviewed in 1, 2).  While it 
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wall (SCW)-induced  arthritis. Arthritis  was induced  with group  A SCWs 
(30 #g rhamnose  i.p./100 gm rat) and TGF-/3 was injected systemically 
(i.p., 1/~g/daily)  or locally  (intraarticular [i.a.], 250 ng/joint, 1 injection 
only). In control (nonarthritic)  rats, TGF-13 alone  was given  systemically 
(1 #g daily)  or locally  (i.a., 3-daily 100 ng injections). Articular  indices 
were determined as described (13, 16). 
is  these  pathways  that  offer  promise  for  TGF-/3  in  im- 
munotherapy, there can be a downside to inducing a state 
of immunologic unresponsiveness,  in that overexpression  or 
parenteral administration of TGF-/3 may convert a natural, 
self-limited infection into one with potentially lethal conse- 
quences  (4,  18,  19). 
The ability of endogenous or pharmacologically elevated 
circulating TGF-/~ in the MRL/Ipr mice to suppress  an- 
timicrobial  functions reflects  TGF-/3's  reported  inhibitory 
influence on reactive oxygen and nitrogen intermediates (8, 
20).  Increased  nitric oxide (NO) generated from t-arginine 
and molecular oxygen is a pivotal mechanism by which mac- 
rophages inhibit a variety of  pathogens, and downregulation 
of the inducible form of NO synthase has been associated 
with reactivation of bacterial  and viral infections (21, 22). 
While the ability of TGF-/3 to dampen widely inducible NO 
generation may have evolved to protect the host from an over- 
abundance of this autotoxic molecule (23, 24), excess TGF-~ 
can have its own problems. Paradoxically,  since TGF-~ in- 
hibits NO, it is somewhat surprising that augmented levels 
of NO and TGF-B coexist in the MRL/lpr mice (4,  25), 
and moreover,  that increased NO does not appear to confer 
any survival  advantage against the bacteria.  These findings 
reiterate the unpredictable nature of a pleiotropic molecule 
such as TGF-/~, and emphasize the impact that this peptide 
may have on host resistance. 
A number of human genetic and acquired diseases are also 
accompanied by a nonspecific immune depression.  The po- 
tent effects of TGF-B on cellular immune pathways resemble 
in many ways those accompanying such autoimmune and in- 
fectious diseases, and elevated circulating levels of TGF-~ have 
been measured in SLE, the human equivalent of the MRL/lpr 
mouse, as well as in HIV-1  infection and arthritis (4,  10, 
26). In the process of defending the host from persistent an- 
tigens or invading pathogens, the overzealous  release of in- 
tended protective molecules such as TGF-/3 can, through its 
endocrine links, have an opposite effect. Under these circum- 
stances,  it may be appropriate to consider employment of 
cytokine antagonists. 
Because TGF-/3 is a critical determinant of so many aspects 
of the host response to injury and infection and to the pro- 
cess of tissue repair, there is considerable interest in its poten- 
tial therapeutic applications.  Taking advantage of the good 
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Figure 2.  Differential  regulation 
of inflammation  by local and sys- 
temic  TGF-3. Summary  of  differen- 
tial effects  of TGF-3 on inflamma- 
tory  cell recruitment  and activation 
after local  administration and ad- 
ministration  through  the circulation. 
T, T lymphocyte;  M, monocyte/ 
macrophage; P, polymorphonuclear 
leukocyte. aspects of TGF-/3's role in inflammation and wound healing, 
local application can be used to promote repair (27, 28) and 
with  a  single  treatment,  the bad aspects of overabundant 
TGF-/3 (excess inflammation and/or fibrosis)  can be averted. 
Conversely, in conditions characterized  by chronic inflam- 
mation and fibrosis (too much TGF-/3), locally active TGF-/3 
antagonists are finding experimental applications (1, 3, 9, 29). 
However, one of TGF-/3's main  therapeutic  attractions  re- 
mains  its promise as an immunosuppressive  agent,  and to 
optimize these mechanisms requires systemic delivery.  Under 
these conditions,  TGF-3 has  disease-limiting  properties  in 
autoimmune and chronic inflammatory diseases, but the very 
mechanisms it suppresses are also those necessary for defense 
against infectious pathogens. Its potentially "ugly" side, pre- 
disposing the patient to uncontrolled infections, must be fac- 
tored into the design of therapeutic strategies. The informa- 
tion presented in the MRL/lpr study suggests that not only 
may aberrant production of endogenous TGF-/3 contribute 
to the high risk of bacterial infections in these animals,  and 
perhaps in lupus and other acquired and genetic diseases, but 
that exogenous TGF-/3 delivered by systemic routes, even in 
a single dose, may have similar manifestations.  Ongoing studies 
in animal models and humans may ultimately enable us to 
manipulate the dose of TGF-3, the route of administration, 
the timing, and other clinically relevant parameters to either 
potentiate or suppress the immune response as best benefits 
the host.  Adjunctive approaches may include manipulation 
of transcriptional  and translational  events involved in con- 
trolling the endogenous synthesis of the peptide and/or its 
natural inhibitors to sculpt the desired immunologic outcome. 
Regulated TGF-3 synthesis during the induction of oral toler- 
ance provides an example of such a directed response (30). 
Even though we know a lot about TGF-/3,  there is still  a 
lot to learn. 
We eagerly awaited the genetically engineered TGF-/3 loss- 
of-function mutation to answer all we ever wanted to know 
about TGF-3, including its role in inflammation and immune 
function, but we found that the TGF-31 gene knockout has, 
as appears  to be typical of this quixotic molecule, provided 
more questions than answers. Although the mice appear sur- 
prisingly normal at birth and for 2-3 wk thereafter, a marked 
leukocyte adhesion to endothelium (31) with infiltration into 
vital organs leads to organ failure, cachexia, and death (32-34). 
This was initially  thought  to be the obvious result of the 
absence of the requisite immunosuppressive actions of TGF- 
/31. However, continued analysis has revealed that the TGF-/31 
knockouts, born to TGF-/3 heterozygous parents, were the 
recipients of maternally transferred TGF-/31 (35), confounding 
the interpretation  of the incipient pathology. Again in this 
model, it is the systemic transport of TGF-/31, occurring pre- 
and  postnatally,  which  yields  an  unpredictable  outcome. 
Maternal TGF-/3, serving as an endocrine source of this mol- 
ecule,  albeit temporary, appears to be sufficient for embryo- 
genesis and birth  of the knockouts, but likely also orches- 
trates their demise. The slacking off of the maternal supply 
of TGF-/31 appears to coincide with the onset of symptoms 
and hypothetically, at least, residual TGF-/31,  in the absence 
of any circulating TGF-/31, may leach or be transported from 
tissue stores to generate a transient chemotactic gradient and 
initiate leukocyte migration  (31). By whatever mechanisms 
this recruitment is triggered, once the inflammatory cells ac- 
cumulate in the tissues,  there is no possibility to generate 
de novo the TGF-/31 required to suppress leukocyte function 
as should occur in the normal  resolution of inflammatory 
events (1, 2). Inexplicably, however, systemically delivered ex- 
ogenous TGF-3 does not reverse  this process, but survival 
can be prolonged if inflammation is suppressed either geneti- 
cally,  by placement of the TGF-/31  targeted allele  onto the 
severe combined immunodeficiency background (TGF-/31 mu- 
tant SCID) (Diebold, K., personal communication), or phar- 
macologically, by blocking adhesion and recruitment  (31). 
The TGF-31 knockout and MRL/lpr models provide im- 
portant paradigms to unravel the ramifications of too much 
or too little TGF-3 on host defense. Paradoxically,  both ex- 
tremes appear to be associated with autoimmune-like  phe- 
nomena.  One thing  is for sure,  there is much  to be done 
if we are to adequately understand  the regulation of and by 
this amazing peptide, in order to develop therapeutic strate- 
gies to use the good, control the bad, and eliminate the ugly 
consequences of TGF-3. 
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